⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
businesswire.com
GMAB
ABBV
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
globenewswire.com
BMY
PFE
AMGN
NVS
MRK
LLY
GILD
AZN
TAK
JNJ
ABBV
CRSP
MOD
ARVN
Global Leaders, Fortune 500 CEOs and Tech Visionaries Convene in Chicago for Second Annual Global Quantum Forum
prnewswire.com
MSFT
CTSH
EXC
IBM
GOOG
JPM
ALL
SO
ABBV
UL
BAC
Neo Launches with $100M to Secure AI Software Across the Enterprise
globenewswire.com
S
PANW
SHOP
NVDA
MSFT
GOOG
AMZN
CRM
ADBE
IBM
INTC
AMD
QCOM
META
TWLO
LI
CVNA
DDOG
CRWD
OKTA
PLTR
SNOW
SMCI
MU
AMAT
LRCX
ASML
ORCL
SAP
CSCO
FTNT
CHKP
VRTX
REGN
GILD
BIIB
AZN
PFE
MRNA
BMY
AMGN
LLY
ABBV
NVO
SNPS
CDNS
MCHP
NXPI
ON
ADI
TXN
CRSP
EXAS
ALGN
TDOC
ROKU
COIN
PYPL
HOOD
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
prnewswire.com
ABBV
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
ANVS
SUPN
ABBV
VNDA
JAZZ
ACAD
MRK
The Ophthalmology Foundation Welcomes Eight Distinguished Leaders to Its Board of Directors
accessnewswire.com
JNJ
ABBV
ENT Disorder Treatment Market to Reach US$58 Billion by 2034, Driven by Digital Diagnostics and Minimally Invasive Car
globenewswire.com
GSK
SNY
PFE
AZN
NVS
ABBV
JNJ
MRK
MDT
SN
BSX
TEVA
SUN